Correction to: EGFR Tyrosine Kinase Inhibitors for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Podcast
(Source: Targeted Oncology)
Source: Targeted Oncology - October 27, 2023 Category: Cancer & Oncology Source Type: research
A Phase 1b/2 Study of Alpelisib in Combination with Cetuximab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
ConclusionsThe addition of alpelisib to cetuximab did not demonstrate a PFS benefit in cetuximab-na ïve patients with advanced HNSCC. The alpelisib–cetuximab combination showed moderate activity in cetuximab-resistant patients, with a consistent safety profile.Clinical Trial RegistrationClinicalTrials.gov NCT01602315; EudraCT 2011-006017-34. (Source: Targeted Oncology)
Source: Targeted Oncology - October 25, 2023 Category: Cancer & Oncology Source Type: research
Back to the Bench: Unveiling the Tissue Context is Crucial to Enhance the Efficacy of Agnostic Therapies in Oncology
(Source: Targeted Oncology)
Source: Targeted Oncology - October 21, 2023 Category: Cancer & Oncology Source Type: research
Intrinsic Resistance to Osimertinib in EGFR Mutated NSCLC Cell Lines Induced by Alteration in Cell-Cycle Regulators
ConclusionsWe conclude that perturbation in cell-cycle regulators leads to intrinsic osimertinib resistance and worse patient outcomes. (Source: Targeted Oncology)
Source: Targeted Oncology - October 19, 2023 Category: Cancer & Oncology Source Type: research
Ivosidenib: A Review in Advanced Cholangiocarcinoma
AbstractIvosidenib (Tibsovo®), a first-in-class, oral small molecule, potent and selective inhibitor of mutant isocitrate dehydrogenase 1 (mIDH1), is approved in the EU and USA for the treatment of adults with pretreated, advanced, mIDH1 cholangiocarcinoma (CCA). It is presumed to exert its cytostatic effects in this setting by suppressing 2-hydroxyglutarate, an oncometabolite produced by mIDH1 that impairs cellular differentiation and promotes tumorigenesis. In the multinational phase 3 ClarIDHy study in patients with pretreated, advanced mIDH1 CCA, monotherapy with ivosidenib once daily significantly prolonged progressi...
Source: Targeted Oncology - October 19, 2023 Category: Cancer & Oncology Source Type: research
Dual PI3K/HDAC Inhibitor BEBT-908 Exhibits Potent Efficacy as Monotherapy for Primary Central Nervous System Lymphoma
ConclusionOur study provides robust evidence for the dual PI3K/HDAC inhibitor BEBT-908 as an effective anti-cancer agent for PCNSL. (Source: Targeted Oncology)
Source: Targeted Oncology - October 19, 2023 Category: Cancer & Oncology Source Type: research
Efficacy and Safety of Niraparib as First-Line Maintenance Treatment for Patients with Advanced Ovarian Cancer: Real-World Data from a Multicenter Study in China
ConclusionsFor Chinese OC patients, niraparib, particularly at a 200 mg individual starting dose, was an effective therapy with easily manageable safety. (Source: Targeted Oncology)
Source: Targeted Oncology - October 17, 2023 Category: Cancer & Oncology Source Type: research
EGFR Tyrosine Kinase Inhibitors for the Treatment of Metastatic Non-small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Podcast
Supplementary file1 (MP4 21169 KB) (Source: Targeted Oncology)
Source: Targeted Oncology - October 4, 2023 Category: Cancer & Oncology Source Type: research
Trastuzumab Deruxtecan: A Review in Gastric or Gastro-Oesophageal Junction Adenocarcinoma
AbstractTrastuzumab deruxtecan (Enhertu®) is a human epidermal growth factor receptor type 2 (HER2)-directed antibody-drug conjugate that is approved in several countries globally for adults with advanced HER2-positive gastric or gastro-oesophageal junction (GOJ) adenocarcinoma who have received a prior trastuzumab-based regime. In the phase II DESTINY-Gastric01 trial, intravenous trastuzumab deruxtecan was significantly more effective than standard chemotherapy (physician ’s choice of intravenous irinotecan or paclitaxel) in achieving objective response and improving overall survival in Japanese or South Korean adults ...
Source: Targeted Oncology - October 3, 2023 Category: Cancer & Oncology Source Type: research
A Systematised Literature Review of Real-World Treatment Patterns and Outcomes in Unresectable Advanced or Metastatic Biliary Tract Cancer
ConclusionsAt the time of this review, treatment options for unresectable advanced or metastatic biliary tract cancers confer poor real-world survival. For over a decade, GEMCIS remained the 1L standard of care, highlighting the lack of therapeutic innovation in this indication and the urgent unmet need for novel treatments with improved outcomes in this aggressive condition. Additional observational studies are needed to further understand the effectiveness of currently available treatments, as well as newly available therapies including the addition of immunotherapy in the evolving treatment landscape. (Source: Targeted Oncology)
Source: Targeted Oncology - September 26, 2023 Category: Cancer & Oncology Source Type: research
Safety of Subcutaneous Daratumumab in Anti-CD38 Monoclonal Antibody-Na ïve Patients with Plasma Cell Disorders: A Multicenter Real-Life Experience
ConclusionsSubcutaneous daratumumab was safe in a real-life setting including patients with severe renal failure and advanced disease. However, further studies on larger and prospective cohorts are required to confirm our real-life observations. (Source: Targeted Oncology)
Source: Targeted Oncology - September 25, 2023 Category: Cancer & Oncology Source Type: research
Results from a Real-World Multicenter Analysis of 482 Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib: A Look at Racial Differences
ConclusionsToxicity and disease progression were the most common reasons for ibrutinib discontinuations in the overall population and among Black patients, respectively. Encouraging research participation of underrepresented patient groups will help clinicians better understand treatment outcomes. (Source: Targeted Oncology)
Source: Targeted Oncology - September 20, 2023 Category: Cancer & Oncology Source Type: research
Correction to: Darolutamide: A Review in Metastatic Hormone-Sensitive Prostate Cancer
(Source: Targeted Oncology)
Source: Targeted Oncology - September 16, 2023 Category: Cancer & Oncology Source Type: research
Population Pharmacokinetics and Exposure –Response with Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma: Results From MajesTEC-1
ConclusionBody weight, myeloma type, and ISS stage impacted systemic teclistamab exposure without any clinically relevant effect on efficacy. The exposure –response analyses for ORR showed a positive trend with increasing teclistamab systemic exposure, with a plateau at the RP2D, and there was no apparent exposure–response trend for safety or other efficacy endpoints. These analyses support the RP2D of teclistamab in patients with RRMM.Clinical Trial RegistrationNCT03145181 (phase I, 09 May 2017); NCT04557098 (phase II, 21 September 2020). (Source: Targeted Oncology)
Source: Targeted Oncology - September 15, 2023 Category: Cancer & Oncology Source Type: research
Impact of Cardiovascular Comorbidities on the Effectiveness and Safety of Bevacizumab in Older Patients with Metastatic Colorectal Cancer
ConclusionsIn clinical practice, cardiovascular comorbidities before administering bevacizumab to older patients with metastatic colorectal cancer impacted the cardiovascular safety, but not overall survival. Unless they limit functional independency, older patients with cardiovascular comorbidities should be treated with bevacizumab under close monitoring. (Source: Targeted Oncology)
Source: Targeted Oncology - September 8, 2023 Category: Cancer & Oncology Source Type: research
